Literature DB >> 1113065

Assessment in vitro of immunity against Toxoplasma gondii.

T C Jones, L Len, J G Hirsch.   

Abstract

Studies have been made on humoral and cellular immune respones in mice immunized with an attenuated strain of Toxoplasma gondii. Heat-inactivated antitoxoplasma serum did not cause morphologic changes in the organisms, but did markedly influence their interactions with host cells. Toxoplasma exposed to antibody were no longer capable of entering fibroblasts or HeLa cells. They were readily engulfed by macrophages, but the antibody treatment strikingly altered the intracellular fate of the parasites leading to killing and digestion of the toxoplasmas in phagolysosomes. Addition of antitoxoplasma antibody immediately after infection of macrophages in vitro had no effect on intracellular multiplication of the organism. The division time of virulent toxoplasmas in mouse peritoneal macrophages in vitro was markedly prolonged in cells from immunized mice. During the first 2-3 mo after immunization, the macrophages harvested from the peritoneal cavity demonstrated this cellular immunity directly; thereafter exposure of the macrophages to immune lymphocytes and toxoplasma antigen, or to supernates from such an interaction was required for induction of the maximal capacity to inhibit growth of toxoplasmas. Induction of the alternation in macrophages by the lymphocyte product was detectable in 6 h and maximal at 18-24 h. Cultivation in vitro of macrophages from immunized animals for periods longer than 48 h rendered the cells nonresponsive to the immune lymphocyte-toxoplasma product. Macrophages from the peritoneal cavities of normal, nonimmunized mice were also incapable of developing the capacity to inhibit growth of toxoplasmas in response to this product. The nonresponsiveness of normal macrophages, or of macrophages cultured for several days in vitro was not changed by exposure of the cells to antitoxoplasma serum.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1113065      PMCID: PMC2190531          DOI: 10.1084/jem.141.2.466

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  33 in total

1.  A TISSUE CULTURE METHOD FOR TITRATION OF INFECTIVITY AND DETERMINATION OF GROWTH RATE OF TOXOPLASMA GONDII. 2.

Authors:  E LYCKE; E LUND
Journal:  Acta Pathol Microbiol Scand       Date:  1964

Review 2.  CELLULAR REACTIONS IN INFECTION.

Authors:  E SUTER; H RAMSEIAR
Journal:  Adv Immunol       Date:  1964       Impact factor: 3.543

3.  Multiplication of three strains of Toxoplasma gondii in tissue culture.

Authors:  H E KAUFMAN; E D MALONEY
Journal:  J Parasitol       Date:  1962-06       Impact factor: 1.276

4.  The inhibitory effect of adenine and related compounds on the proliferation of Toxoplasma gondii in tissue culture.

Authors:  M K COOK
Journal:  J Parasitol       Date:  1958-06       Impact factor: 1.276

5.  Intracellular multiplication of Toxoplasma gondi in adult mammalian macrophages cultivated in vitro.

Authors:  W A VISCHER; E SUTER
Journal:  Proc Soc Exp Biol Med       Date:  1954-07

6.  The effect of lymphocyte supernatant fluids on the intracellular growth of virulent tubercle bacilli.

Authors:  C L Klun; G P Youmans
Journal:  J Reticuloendothel Soc       Date:  1973-03

7.  Further studies on the inhibition of Histoplasma capsulatum within macrophages from immunized animals.

Authors:  D H Howard
Journal:  Infect Immun       Date:  1973-10       Impact factor: 3.441

8.  Demonstration in tissue culture of lymphocyte-mediated immunity to tuberculosis.

Authors:  R J Patterson; G P Youmans
Journal:  Infect Immun       Date:  1970-06       Impact factor: 3.441

9.  Effect of normal and activated human macrophages on Toxoplasma gondii.

Authors:  S E Anderson; J S Remington
Journal:  J Exp Med       Date:  1974-05-01       Impact factor: 14.307

10.  Cellular resistance to infection.

Authors:  G B MACKANESS
Journal:  J Exp Med       Date:  1962-09-01       Impact factor: 14.307

View more
  52 in total

1.  Host defenses in experimental scrub typhus: role of normal and activated macrophages.

Authors:  C A Nacy; J V Osterman
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

2.  Growth of eimeria tenella in vitro in macrophages from chicken peritoneal exudates.

Authors:  P L Long; M E Rose
Journal:  Z Parasitenkd       Date:  1976-02-06

3.  Vaccine-induced immunity against cutaneous leishmaniasis in BALB/c mice.

Authors:  D Frommel; B W Ogunkolade; I Vouldoukis; L Monjour
Journal:  Infect Immun       Date:  1988-04       Impact factor: 3.441

4.  In vitro cultivation of Toxoplasma gondii cysts in astrocytes in the presence of gamma interferon.

Authors:  T C Jones; K A Bienz; P Erb
Journal:  Infect Immun       Date:  1986-01       Impact factor: 3.441

5.  Impaired antibody-dependent cell-mediated cytotoxic activity in patients with the acquired immunodeficiency syndrome.

Authors:  B S Bender; F A Auger; T C Quinn; R Redfield; J Gold; T M Folks
Journal:  Clin Exp Immunol       Date:  1986-04       Impact factor: 4.330

Review 6.  Effector cells, molecules and mechanisms in host-protective immunity to parasites.

Authors:  G F Mitchell
Journal:  Immunology       Date:  1979-10       Impact factor: 7.397

7.  Effect of alveolar macrophages on Toxoplasma gondii.

Authors:  F W Ryning; J S Remington
Journal:  Infect Immun       Date:  1977-12       Impact factor: 3.441

8.  Legionnaires' disease bacterium (Legionella pneumophila) multiples intracellularly in human monocytes.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

9.  Localization of azithromycin in Toxoplasma gondii-infected cells.

Authors:  J C Schwab; Y Cao; M R Slowik; K A Joiner
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

10.  Effect of cyclophosphamide on Toxoplasma gondii infection: reversal of the effect by passive immunization.

Authors:  A Hafizi; F Z Modabber
Journal:  Clin Exp Immunol       Date:  1978-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.